Constarium
← Search

Data · dataset · 2026

Cardiovascular effects of dapagliflozin in patients on chronic dialysis: the DARE-ESKD-2 randomized clinical trial

Listed in REDU - Unicamp Institutional Research Data Repository

This dataset encompass Dare-Eskd-2 trial information, a prospective, randomized, open-label, blinded endpoint trial performed at 3 dialysis clinics between January 2023 and September 2024, that enrolled 80 consecutive adults on chronic dialysis to either once daily dapagliflozin 10mg or standard care for 24 weeks.

Description

Efficacy endpoints comprised the change from baseline to 24 weeks in NT-proBNP, KCCQ-CCS, 6-minute walk test distance.

Links

Where it is published

Catalogue records · 1

Topics

Provenance · 1 source records, 10 field assertions
SourceKeyLast seenRaw
REDU - Unicamp Institutional Research Data Repositorydoi:10.25824/redu/OXTXSM9 d agoJSON v1
FieldAssertionExtractorEvidence
concepts[field].anzsrc:field:320101mapping · redu unicamp brvocabulary-mapper@1.0.0keywords['Cardiology']
concepts[field].dataverse_subject:medicine-health-and-life-sciencessource · redu unicamp brconnector:redu_unicamp_br@1.0.0/subjects
concepts[field].local:field:life-sciencesmapping · redu unicamp brconnector:redu_unicamp_br@1.0.0/subjects
concepts[field].local:field:medicine-healthmapping · redu unicamp brconnector:redu_unicamp_br@1.0.0/subjects
created_datesource · redu unicamp brconnector:redu_unicamp_br@1.0.0
descriptionsource · redu unicamp brconnector:redu_unicamp_br@1.0.0/description
publication_datesource · redu unicamp brconnector:redu_unicamp_br@1.0.0
titlesource · redu unicamp brconnector:redu_unicamp_br@1.0.0/name
updated_datesource · redu unicamp brconnector:redu_unicamp_br@1.0.0
version_labelsource · redu unicamp brconnector:redu_unicamp_br@1.0.0